Condition: High Grade Glioma · MGMT-Unmethylated Glioblastoma · MGMT-Methylated Glioblastoma · Sponsor: University of California, San Francisco
This is a multicenter, open-label study of DB107-RRV (formerly Toca 511) and DB107-FC (formerly Toca FC) when administered following surgical resection in newly diagnosed High Grade Glioma (HGG) patients. The study is designed to evaluate whether treatment with DB107-RRV in combination with DB107-FC when added to standard of care provides clinical benefit to newly diagnosed HGG when compared to historical performance previously determined in well controlled clinical trials published in the peer reviewed literature. This study is going to be conducted in newly diagnosed HGG patients receiving with maximum surgical resection treatment followed by radiation and temozolomide treatment using the established Stupp Protocol for O6-methylguanine-DNA methyl-transferase (MGMT) methylated patients or radiation therapy for MGMT unmethylated patients.
This description comes directly from the study's public registry record.
Stephanie Lewis, RN · (415) 353-2193 · stephanie.lewis2@ucsf.edu
Neuro-Oncology New Patient Coordinator · NeuroOncNewPatientCoord@ucsf.edu
Always discuss trial participation with your own doctor first.
| University of Southern California | Los Angeles, California, United States | Recruiting |
| University of California, San Diego | San Diego, California, United States | Recruiting |
| University of California | San Francisco, California, United States | Recruiting |
| University of Miami | Miami, Florida, United States | Recruiting |
| Northwell Health | Lake Success, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06504381